Pattern Pharma is an North American immunotherapy company whose P2PAR product systemically activates the innate immune system (dendritic cells, macrophages and NK cells) to fight infectious diseases and cancers.  P2PAR is newly patent-protected and is the next generation of a product which earlier received regulatory approval in an ex-US jurisdiction, where it has proven safe & efficacious during widespread use on patients in several indications. Pattern’s focus is on leveraging the large body of existing data and experience in order to obtain regulatory approvals for P2PAR in the US, Europe, Asia and other key markets.